GRI
GRI Bio, Inc. Common StockstockNASDAQ
gri is a development stage biotech company fundamentally changing the way inflammatory disease is treated. gri's natural killer t (nkt) cell-based therapies are being developed for liver disease and acute liver failure. nkt cells share properties of both nk and t cells and are a functional link between the innate and adaptive immune responses. type 1 nkt cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. gri's lead program, gri-0621, is an inhibitor of type i nkt cells and is being developed as a novel oral therapeutic for acute liver failure.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.82 | 2026-11-12 | -35.71% | 6.688 |
| 1M | 1.45 | 2026-10-19 | -19.31% | -0.290 |
| 3M | 1.73 | 2026-08-19 | -32.37% | 0.727 |
| 6M | 2.23 | 2026-05-19 | -47.53% | 0.348 |
| 1Y | 47.32 | 2025-11-19 | -97.53% | 0.626 |
| 2Y | 326.20 | 2024-11-19 | -99.64% | — |
| 5Y | 371,867.86 | 2023-04-24 | -100.00% | 0.941 |
GRI Bio, Inc. Common Stock (NASDAQ:GRI) stock price today is $1.17, and today's volume is 23,712. GRI is down 7.874% today. The 30 day average volume is 46,709. GRI market cap is $2.56M with 2.19M shares outstanding.